MedTrace Logo

Glucose Regulation During Risperidone and Olanzapine Treatment

NCT00006195 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2006-10-12

No results posted yet for this study

Summary

The overall purpose of this research is to look at how two of the most commonly prescribed newer antipsychotic medications, risperidone and olanzapine, affect substances in the body such as glucose and insulin. Undesirable changes in blood sugar control, or glucose regulation, and type 2 diabetes can occur more commonly in individuals with schizophrenia compared to healthy subjects and subjects with other psychiatric conditions. While abnormalities in glucose regulation were first reported in schizophrenia before the introduction of antipsychotic medications, antipsychotic treatment may contribute significantly to abnormalities in glucose regulation. Attention to the way that antipsychotic medications may affect glucose regulation has increased as doctors have become more concerned in general about disease- and drug-related medical complications, including weight gain during antipsychotic treatment.

Conditions

Interventions

DRUG

risperidone

DRUG

olanzapine

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Washington University School of Medicine

    collaborator OTHER

  • National Center for Research Resources (NCRR)

    lead NIH

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006195 on ClinicalTrials.gov